The intended use population are those patients for whom the therapeutics or diagnostics are intended to be used. The target population of a clinical trial is the broad group of people that researchers examine because they think those patients might benefit from a particular experimental drug. The specific condition a drug is intended to treat is referred to as that drug’s indication. Drug developers sometimes conduct clinical trials for drugs that have already been approved by the FDA in order to determine whether or not they can be used for additional or expanded indications or populations (e.g., a drug may be approved for a specific subset of patients with non-small cell lung cancer [NSCLC] and later be evaluated and approved for the general population of patients with NSCLC).